Compare Aurobindo Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs FULFORD INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA FULFORD INDIA AUROBINDO PHARMA/
FULFORD INDIA
 
P/E (TTM) x 17.3 398.8 4.3% View Chart
P/BV x 3.7 6.2 60.1% View Chart
Dividend Yield % 0.3 0.1 333.0%  

Financials

 AUROBINDO PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
FULFORD INDIA
Mar-14
AUROBINDO PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs830942 88.1%   
Low Rs527450 117.1%   
Sales per share (Unadj.) Rs333.9691.4 48.3%  
Earnings per share (Unadj.) Rs40.411.5 352.1%  
Cash flow per share (Unadj.) Rs51.815.4 337.0%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.3 128.2%  
Book value per share (Unadj.) Rs237.1380.0 62.4%  
Shares outstanding (eoy) m585.913.90 15,023.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.0 201.9%   
Avg P/E ratio x16.860.7 27.7%  
P/CF ratio (eoy) x13.145.3 28.9%  
Price / Book Value ratio x2.91.8 156.3%  
Dividend payout %6.217.4 35.5%   
Avg Mkt Cap Rs m397,5692,714 14,646.7%   
No. of employees `00017.90.4 4,021.4%   
Total wages/salary Rs m25,849505 5,118.6%   
Avg. sales/employee Rs Th10,956.96,073.0 180.4%   
Avg. wages/employee Rs Th1,447.71,137.4 127.3%   
Avg. net profit/employee Rs Th1,324.3100.7 1,315.4%   
INCOME DATA
Net Sales Rs m195,6362,696 7,255.4%  
Other income Rs m1,553125 1,238.6%   
Total revenues Rs m197,1892,822 6,988.0%   
Gross profit Rs m39,519-46 -85,171.1%  
Depreciation Rs m6,68015 43,944.1%   
Interest Rs m2,62610 27,642.1%   
Profit before tax Rs m31,76754 58,502.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,26910 75,713.5%   
Profit after tax Rs m23,64545 52,897.1%  
Gross profit margin %20.2-1.7 -1,173.9%  
Effective tax rate %22.917.7 129.4%   
Net profit margin %12.11.7 729.1%  
BALANCE SHEET DATA
Current assets Rs m153,6451,738 8,838.8%   
Current liabilities Rs m120,429545 22,109.2%   
Net working cap to sales %17.044.3 38.4%  
Current ratio x1.33.2 40.0%  
Inventory Days Days13548 279.0%  
Debtors Days Days644 1,479.6%  
Net fixed assets Rs m103,90912 873,182.4%   
Share capital Rs m58639 1,502.3%   
"Free" reserves Rs m138,3221,443 9,585.7%   
Net worth Rs m138,9081,482 9,373.0%   
Long term debt Rs m1,8000-   
Total assets Rs m264,5442,077 12,738.7%  
Interest coverage x13.16.7 195.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.3 57.0%   
Return on assets %9.92.6 380.5%  
Return on equity %17.03.0 564.4%  
Return on capital %23.84.3 553.7%  
Exports to sales %49.60-   
Imports to sales %18.824.5 76.8%   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741659 5,572.9%   
Fx inflow Rs m97,31617 565,793.0%   
Fx outflow Rs m40,589673 6,029.7%   
Net fx Rs m56,727-656 -8,648.0%   
CASH FLOW
From Operations Rs m16,22090 18,022.6%  
From Investments Rs m-28,768105 -27,503.2%  
From Financial Activity Rs m19,191-14 -136,103.5%  
Net Cashflow Rs m6,656181 3,687.8%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 3.8 209.2%  
FIIs % 27.7 0.1 27,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.2 48.1%  
Shareholders   69,601 4,783 1,455.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  NEULAND LABS  FRESENIUS KABI ONCO.  ALEMBIC PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 447 Points Higher; Automobile & IT Stocks Rally(Closing)

Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Mar 2, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS